Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 65 of 1,261
  1. US 12213985

    Oral cannabinoid formulations

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  2. US 12213964

    Isoxazoline parasiticide formulations

    Tarsus Pharmaceuticals, Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  3. US 12215108

    Development of potential antidotes for arsenicals

    United States Government as represented by the Department of Veterans Affairs · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  4. US 12213941

    Adapter for use in a planetary mixer

    MEDISCA PHARMACEUTIQUE INC. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  5. US 12215133

    GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use

    BrightGene Bio-Medical Technology Co., Ltd. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  6. US 12215135

    PDL2 compounds

    IO Biotech ApS · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  7. US 12214083

    Pharmaceutical composition and administrations thereof

    Vertex Pharmaceuticals Incorporated · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  8. US 12214031

    Mannheimia haemolytica vector

    The United States of America, as represented by the Secretary of Agriculture · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  9. US 12215090

    Agents and methods for treating dysproliferative diseases

    Tri-Institutional Therapeutics Discovery Institute, Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  10. US 12215162

    BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof

    The Board of Regents of the University of Texas System · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  11. US 12215316

    Materials and methods for treatment of usher syndrome type 2A

    CRISPR THERAPEUTICS AG · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  12. US 12215169

    Anti-complement C1s antibodies and uses thereof

    Bioverativ USA Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  13. US 12213951

    Treatment of autism with cannabidiol

    Harmony Biosciences Management, Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  14. US 12215320

    Compositions and methods for gene editing by targeting transferrin

    CRISPR THERAPEUTICS AG · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  15. US 12215343

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  16. US 12215148

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  17. US 12215349

    Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  18. US 12215355

    Stem cell derived islet differentiation

    Vertex Pharmaceuticals Incorporated · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  19. US 12213977

    Methods and compositions for treating melanoma

    The Regents of the University of California · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  20. US 12219327

    Substituted isoindolines as PI3K-alpha inhibitors

    Relay Therapeutics, Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  21. US 12215105

    HPK1 antagonists and uses thereof

    Nimbus Saturn, Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  22. WO 2025023851

    ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE

    BIAL PORTELA & CA SA [PT] · Granted Jan 30, 2025 · Expires Jan 25, 2045

    granted
  23. WO 2025023852

    ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE

    BIAL PORTELA & CA SA [PT] · Granted Jan 30, 2025 · Expires Jan 25, 2045

    granted
  24. US 2025034157

    PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

    ABBVIE INC [US] · Granted Jan 30, 2025 · Expires Jan 25, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.